Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Search results for: “patient perspective”

  • Member Story: Dr. Amy Moore

    Member Story: Dr. Amy Moore

    By

    Member Stories from the COVID-19 Era

    Dr. Amy Moore—USA Dr. Amy Moore is the Director of Science and Research for the GO2 Foundation for Lung Cancer and based in the San Francisco Bay area, shares her thoughts on the current COVID-19 pandemic and what it means for the lung cancer community. I guess my perspective is a unique one because my doctorate…

  • Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

    Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

    By

    Diagnostic Oncology

    By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients with lung cancer has been described extensively by many experts within the IASLC.1,2 There are, however, broad disparities in outcomes for patients with lung cancer…

  • Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC

    Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC

    By

    Evolving Standards of Care

    By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of advanced oncogene-driven NSCLC.1,2 Despite initial high response rates, durable and complete responses are rare, and most patients eventually experience treatment failure.3 Residual disease is defined…

  • Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

    Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

    By

    Evolving Standards of Care

    Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and other oncogenic drivers has helped further lung cancer research and patient care. In the…

  • A Balancing Act: Managing Patients’ Expectations

    A Balancing Act: Managing Patients’ Expectations

    By

    Patient Advocacy & Survivorship

    By Leah Lawrence Posted: December 11, 2019 Many patients newly diagnosed with lung cancer have difficulty navigating the world of cancer when unexpectedly and unwillingly thrust into it. In addition to understanding their diagnosis, prognosis, and treatment options, patients are also bombarded with an abundance of information on the internet, direct-to-consumer advertising of new cancer…

  • STARS Patient Research Advocate Training Program Seeks Patients and Caregivers

    STARS Patient Research Advocate Training Program Seeks Patients and Caregivers

    By

    Patient Advocacy & Survivorship

    By Adam Mohrbacher Posted: December 11, 2019 Patients with lung cancer and their caregivers are becoming more empowered and knowledgeable than ever. As a result, lung cancer now has a growing group of patients who have lived long enough to become advocates for their disease. Some are evolving into research advocates— volunteers with a personal…

  • From Patient to Patient Research Advocate: The STARS Journey

    From Patient to Patient Research Advocate: The STARS Journey

    By

    Patient Advocacy & Survivorship

    By Adam Mohrbacher Posted: December 11, 2019 With the rise of organized lung cancer patient advocacy groups,1 patients, advocates, and caregivers are now playing a larger role than ever in raising awareness, providing education, and even driving research into the disease. In order to support this groundswell of passion and advocacy, the IASLC’s Supportive Training…

  • Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

    Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

    By

    Regulatory Agency Perspective

    Posted: December 11, 2019 In June 2019, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence launched Project Facilitate, a call center that assists oncology healthcare professionals with the submission process involved in obtaining unapproved therapies for individual patients with cancer via the Expanded Access program.1 Richard Pazdur, MD, director of the FDA…

  • Palliative Care: Combating Stigma and Enhancing Quality of Care – A Worldwide Perspective

    Palliative Care: Combating Stigma and Enhancing Quality of Care – A Worldwide Perspective

    By

    Supportive & Palliative Care

    By Corey J. Langer, MD, FACP Posted: December 11, 2019   Dr. Corey Langer Jennifer Temel, MD, and colleagues1 showed in a small but well-conducted phase III trial that a proactive, intensive palliative care program compared to our more typical reactive approach could lead to improved outcomes in advanced NSCLC, including better quality of life,…

  • IASLC’s Inaugural Mesothelioma Meeting Sets Baseline for Strategic Approach to Patient Care

    IASLC’s Inaugural Mesothelioma Meeting Sets Baseline for Strategic Approach to Patient Care

    By

    Meeting News

    Posted: November 15, 2019 As a rare orphan disease, mesothelioma research has been slowed by a lack of eligible patients for trials and by a dearth of resources. Because of these hurdles, agreement among oncologists and researchers in the field regarding strategic priorities is necessary. The IASLC 2018 Mesothelioma Meeting held this past July in…

View ILCN Archives

Provider Resources

Popular Articles